Diabetes Information

Benfotiamine - A New Tool In Preventing Diabetic Complications?


Benfotiamine made headlines globally in 2003 when researchers released information about a study that was conducted at The Einstein College of Medicine in New York. The bottom line of this study was that a substance of the allithiamine group of the naturally occurring thiamine-derived compounds had positive effects on neuropathy, retinopathy and nephropathy and heart/circulatory problems in diabetics.

Benfotiamine research has suggested that there are beneficial effects for diabetics and non-diabetics also. These benefits include sciatica, vascular health, general nerve health, lower blood pressure, grant cellular protection, anti-aging, fibromyalgia, prevention of lactic acidosis, and treatment for Alzheimer's disease. Any condition that is the result of a thiamine deficiency will also respond quite well to benfotiamine. Of course, any bodily function that is improved by a therapeutic level of thiamine will certainly be enhanced by benfotiamine, since benfotiamine is perhaps the most effective form of thiamine.

Benfotiamine, a derivative of thiamine (vitamin B1), was an invention of Japanese scientists and there is a U.S. patent on benfotiamine that was entered by the Japanese back in 1962. Japanese benfotiamine is considered the purest source of bulk benfotiamine and is favored by manufacturers globally who insist on the highest quality in their benfotiamine product.

The safety of benfotiamine use has been proven over 12 years of use in Europe for the treatment and prevention of diabetic complications among others. The original Japanese patent on benfotiamine gave information that it is even less toxic than common vitamin B1 (thiamine hydrochloride usually). Orally ingested vitamin B1 has a long history of use as an oral supplement without reported adverse effects. Due to its therapeutic action in some frequently observed clinical syndromes, thiamine hydrochloride has been advised and used over a long period of time. There are no reports of adverse effects of oral thiamine, even at dosages of several hundred milligrams a day (SCOGS, 1978; DHEW, 1979; Marks, 1989).

Benfotiamine has a very good safety record. To date, there has been no reports of any known, negative interactions with any medications. To the contrary, some medications actually can cause a thiamine deficiency in some people and benfotiamine could correct this serious situation.

Many researchers, medical experts, doctors, podiatrists and many medical publishers recommend benfotiamine for neuropathy, retinopathy nephropathy, heart/circulatory complications and B1 deficiencies. Any in depth study on the web will produce physicians, naturopaths, neurologists, optometrists, chiropractors, etc. who have very positive feelings about the effectiveness and potential of benfotiamine in terms of the research done to date on this important tool in the arsenal against neuropathy, retinopathy and beneficial for the heart and circulatory system. We have professional healthcare providers from all of these disciplines which shows the confidence the medical community has in the purity and bioavailability of our benfotiamine product.

Dr. David Williams, publisher of "Alternatives Newsletter", wrote an in depth article concerning benfotiamine in his May, 2004 issue. This article is an eye opener in terms of how effective benfotiamine can be for many health conditions. If possible, it would be beneficial for any interested reader to take a look at this article. For more information about this article you may contact the author below.

Dr Paul Chous is another medical professional who sees the merits of benfotiamine:

"I suspect strongly that benfotiamine will mitigate (or, hopefully, prevent) DRT in humans, but the burden of proof has not yet been met. The case for symptomatic relief of neuropathy symptoms is, of course, more tangible." http://www.emuhealthproducts.com/drchous.html

In conclusion, the consensus for benfotiamine is very positive and are worth investigating. If you or anyone you know is a diabetic, the great possibility of developing diabetic complications over time makes benfotiamine a viable tool in the arsenal for protection. If they are already experiencing complications such as neuropathy, retinopathy, and others, they will benefit from possible reduction in the progression along with pain relief in terms of peripheral neuropathy and other neuropathies.

Zach Malott is CEO of Brentwood Health International, a nutritional supplement company involved in distribution and supplying wholesale, retail and end users.

Mr. Malott is available to discuss the research as it applies to benfotiamine in the treatment and prevention of diabetic complications such as neuropathy and retinopathy.

He can be reached at:

Phone: 505.354.0526

Website: http://www.emuhealthproducts.com


MORE RESOURCES:

MiamiHerald.com

Corporate Watch
Wall Street Journal
Despite clinical data suggesting a link between Seroquel and increased risk for diabetes, AstraZeneca's primary legal argument is that there is no evidence ...
AstraZeneca Wins Trial on Seroquel Diabetes ClaimBusinessWeek
AstraZeneca wins US liability case on SeroquelReuters
AstraZeneca wins 1st trial over alleged drug harmThe Associated Press
Drug Store News -ONN.tv -RTT News
all 163 news articles »


World News

Manage diabetes to preventing heart disease and stroke
The Morning Sun
By MIDMICHIGAN HEALTH Heart disease is common in people with diabetes, but the good news is that taking good care of diabetes and the body today can help ...
Right Knowledge and Conduct is the Key to Survive with DiabetesTopNews United States
Online, Phone Tests Assess Diabetes RiskBusinessWeek
Education, behavior key to living with diabetesNews-Herald.com
Medscape -UPI.com -About - News & Issues (blog)
all 112 news articles »



Quad-Cities Online

Health department home health staff note American Diabetes Alert Day
Quad-Cities Online
The Henry and Stark County Health Departments' Home Health Nursing staff announce that Tuesday, March 23rd has been proclaimed the American Diabetes Alert ...
Diabetes health fair Saturday -- at the cemeteryAustin American-Statesman (blog)
'Diabetes Alert Day' is March 23TriValley Central
"The silent killer"San Jose Mercury News
Medical News Today (press release) -Diabetes.co.uk -Marketwire (press release)
all 16 news articles »


India Talkies

Selenium Could Shield Against Diabetes
BusinessWeek
THURSDAY, March 18 (HealthDay News) -- Scientists have found evidence that older men with higher levels of selenium are less likely to suffer from ...
Dietary supplement can reduce diabetes risk – but only in menTelegraph.co.uk
Selenium may help fight diabetes in menTimes of India
Dietary Supplement Can Lower Risk of Diabetes Just in MenDiet.co.uk
eMaxHealth -Diabetes.co.uk -TopNews United States
all 31 news articles »


Daily Contributor

FDA Rejects Amylin Diabetes Drug, Seeks More Info
Wall Street Journal
NEW YORK (Dow Jones)--The US Food and Drug Administration denied approval of a long-acting version of diabetes drug ...
Diabetes Drug From Lilly, Amylin Under ScrutinyForbes
FDA asks for risk plan info on diabetes drugThe Associated Press
Alkermes, others rise on Byetta newsBoston Globe
BusinessWeek -Cincinnati.com -Xconomy
all 313 news articles »


Reuters

A Diagnosis of Pre-Diabetes Isn't Enough to Motivate Many Patients
Diabetes Health (press release)
In a study that tracked 1402 people with pre-diabetes, researchers found that only about half of them responded to the diagnosis by trying to shed weight or ...
Diabetes Mellitus - an increasing problemLiberty County Times
Blood exam predicts risk for diabetesPaducah Sun
Are You At Risk For Diabetes?NJ TODAY
Reuters -Gather.com -India Infoline.com
all 26 news articles »


Bristol combination diabetes drug under review
BusinessWeek
Onglyza, made by Bristol-Myers and AstraZeneca, is already approved as a diabetes treatment and metformin is a widely-used generic diabetes pill. ...
FDA Approves Another Type 2 Diabetes Drug ApplicationeMaxHealth
Bristol-Myers Squibb, AstraZeneca Say FDA Accepts NDA For An Onglyza ...RTT News
Market Report -- In Play (BMY)MSN Money
News-Medical.net
all 22 news articles »


Studies: Drugs don't reduce heart problems for diabetes patients
USA Today
They involve people with Type 2 diabetes — the most common form and the one rising because of the obesity epidemic. Diabetics have more than double the risk ...

and more »


Has Roche Given Up On Diabetes Devices?
Forbes
Listening to O'Day speak one would never know that Roche is even in the business of diabetes devices. Granted this unit has struggled mightily over the past ...


Google News

home | site map
© 2006